a transcriptional regulator central in Th2 cell differentiation. Inhibits breast cancer growth and pulmonary breast cancer metastasis. Represses INK4C transcription, constrains luminal progenitor cell expansion, and suppresses luminal tumorigenesis in the mammary gland. High GATA3 and low INK4C expression predicts a favorable patient outcome in luminal A type breast tumors. IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human T cells. GATA3 haploinsufficiency leads to HDR (hypoparathyroidism, deafness, and renal dysplasia) syndrome. Two alternatively spliced human isoforms have been described. Note: This description may include information from UniProtKB.
Molecular Function: chromatin binding; DNA binding; protein binding; transcription coactivator activity; transcription factor activity; transcription factor binding
Biological Process: anatomical structure formation; anatomical structure morphogenesis; blood coagulation; cell fate commitment; cell fate determination; defense response; ear development; gut development; heart development; kidney development; male gonad development; mesonephros development; negative regulation of cell cycle; negative regulation of cell proliferation; negative regulation of fat cell differentiation; negative regulation of inflammatory response; negative regulation of mammary gland epithelial cell proliferation; negative regulation of transcription, DNA-dependent; norepinephrine biosynthetic process; organ morphogenesis; pharyngeal system development; phosphoinositide 3-kinase cascade; positive regulation of interleukin-4 production; positive regulation of protein kinase B signaling cascade; positive regulation of signal transduction; positive regulation of T cell differentiation; positive regulation of transcription from RNA polymerase II promoter; positive regulation of transcription, DNA-dependent; regulation of cytokine biosynthetic process; response to estrogen stimulus; response to virus; signal transduction; sympathetic nervous system development; T cell receptor signaling pathway; TOR signaling pathway; uterus development
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.